With the European Commission labeling the Grail takeover anti-competitive, Illumina may have to undo the deal and pay a fine of as much as 10% of its annual revenue. While Grail has progressed since the Illumina deal, it also has delivered data that lowered expectations for its multi-cancer screening test, with the positive predictive value in a key trial falling between the interim and final analyses.